CSL vs GSK vs Pfizer and 1 More Revenue Comparison
Compare financial metrics side-by-side using real SEC EDGAR data
Revenue Comparison
Chart: Revenue Comparison. Values in USD billions. In Q2 2026: CSL 3.6525, GSK 11.109, Pfizer 16.583, Merck & Co. 18.085.
* CSL reports semi-annually. Values are evenly split across both quarters within each half.
Latest Quarter Comparison
Table: Latest Quarter Comparison. 15 rows across Metric, CSL, GSK, Pfizer, Merck & Co..| Metric | CSL | GSK | Pfizer | Merck & Co. |
|---|---|---|---|---|
| Market Cap | $64.44B | $97.38B | $159.94B | $339.66B |
| Revenue | $7.30B | $11.11B | $16.58B | $18.09B |
| Cost of Revenue | $4.06B | $2.84B | $4.03B | $4.89B |
| Gross Profit | $3.24B | $8.27B | $12.55B | $13.19B |
| Operating Income | $1.39B | $3.21B | $3.67B | $5.59B |
| Net Income | $-2.94B | $1.93B | $3.24B | $5.07B |
| R&D Expense | $614.00M | $2.34B | $3.02B | $4.54B |
| Earnings Per Share | -$6.14 | $0.96 | $0.56 | $2.04 |
| Gross Margin | 44.4% | 74.5% | 75.7% | 73.0% |
| Operating Margin | 19.0% | 28.9% | 22.1% | 30.9% |
| Net Profit Margin | -40.2% | 17.4% | 19.6% | 28.0% |
| Free Cash Flow | $1.76B | $3.04B | $4.80B | $5.52B |
| Cumulative Free Cash Flow | $21.56B | $160.25B | $361.51B | $255.22B |
| Operating Cash Flow | $2.09B | $3.51B | $5.38B | $6.56B |
| Cash & Equivalents | $1.51B | $3.72B | $1.82B | $9.55B |